MYOCD and esophageal cancer: ABI3BP can serve as a potential biomarker for the diagnosis of esophageal cancer and an effective target for anti-tumor therapy.[24] Furthermore, in non-small cell lung cancer, MYOCD overexpression drives TGF-β-induced epithelial-mesenchymal transition (EMT), which stimulates the non-small cell lung cancer cells metastasis in vivo.[25]PGM5 is a potential colorectal cancer protein marker in a large number of patients.[26] Therefore, these genes may be potential drivers for LUSC cancer.